A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

Cohorts 2 and 3: MRR as assessed by the IRC

MRR is defined as the percentage of participants achieving PR or better.

Time frame: Up to approximately 5 years

All Cohorts: MRR as assessed by the Investigator

MRR is defined as the percentage of participants achieving PR or better.

Time frame: Up to approximately 5 years

Cohorts 1, 2, and 3: Duration of Major Response (DoMR) as assessed by the IRC

DoMR is defined as the time from first determination of major response until first documentation of progression or death, whichever occurs first.

Time frame: Up to approximately 5 years

All Cohorts: DoMR as assessed by the Investigator

DoMR is defined as the time from first determination of major response until first documentation of progression or death, whichever occurs first.

Time frame: Up to approximately 5 years

Cohorts 1, 2, and 3: Complete Response (CR) + Very Good Partial Response (VGPR) as assessed by the IRC

CR + VGPR is defined as the percentage of participants who achieve CR or VGPR.

Time frame: Up to approximately 5 years

All Cohorts: CR + VGPR as assessed by the Investigator

CR + VGPR is defined as the percentage of participants who achieve CR or VGPR.

Time frame: Up to approximately 5 years

Cohorts 1, 2, and 3: Overall Response Rate (ORR) as assessed by the IRC

ORR is defined as the percentage of participants with minor response (MR) or better.

Time frame: Up to approximately 5 years

All cohorts: ORR as assessed by the investigator

ORR is defined as the percentage of participants with MR or better.

Time frame: Up to approximately 5 years

Cohorts 1, 2, and 3: Duration of Response (DOR) as assessed by the IRC

DOR is defined as the time from first determination of response until first documentation of progression or death, whichever occurs first.

Time frame: Up to approximately 5 years

All Cohorts: DOR as assessed by the investigator

DOR is defined as the time from first determination of response until first documentation of progression or death, whichever occurs first.

Time frame: Up to approximately 5 years

Cohorts 1, 2, and 3: Progression-Free Survival (PFS)

PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC and by the investigator.

Time frame: Up to approximately 5 years

Cohorts 1, 2, and 3: Time to major response as assessed by the IRC

Time to major response is defined as the time from start of study treatment to the first documentation of major response.

Time frame: Up to approximately 5 years

All Cohorts: Time to major response as assessed by the investigator

Time to major response is defined as the time from start of study treatment to the first documentation of major response.

Time frame: Up to approximately 5 years

Cohorts 1, 2, and 3: Overall Survival (OS)

OS is defined as the time from first study drug administration to the date of death due to any cause.

Time frame: Up to approximately 5 years

Cohort 4: Time to next treatment

Defined as the time from the start of treatment to the start of first subsequent therapy for WM.

Time frame: Up to approximately 5 years

Number of participants reporting adverse events

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory abnormalities, physical examination results, and vital signs.

Time frame: Up to approximately 5 years

All Cohorts: Change from Baseline in Health-Related Quality of Life (HRQoL): NFLymSI-18 Disease-related Symptoms-Physical and Treatment-Related Side Effects Subscales

HRQoL based on participant-reported outcomes using National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index - 18 Item (NFLymSI-18) Version 4. The questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and is divided into a total score.

Time frame: Baseline and approximately months 7, 13, 19, and 25